A Monthly Injectable Extended-Release Buprenorphine May Reduce Staffing Time & Costs For Opioid Treatment In Jails & Prisons, Simulation Finds
A monthly injectable formulation of extended-release buprenorphine (branded as Sublocade) used to treat jail and prison inmates with opioid use disorder (OUD) may require less staff time to administer than other types of medication for opioid use disorder (MOUD), according to a simulation model.
The model compared staffing hours and costs associated with administering different MOUD options to treat 100 incarcerated individuals. The reduction in staff administration time for Sublocade resulted in monthly cost savings ranging from $23 to $22,148 compared to other types of MOUD.
The largest reductions in staff time were observed when comparing Sublocade to . . .
